background
clinic
featur
incid
human
coronaviru
hcov
infect
chronic
ill
older
adult
need
better
definit
method
hcov
infect
determin
basi
increas
serum
antibodi
detect
hcov
reversetranscript
polymeras
chain
reaction
laboratorydocu
influenza
ldi
detect
serolog
assay
cultur
hcov
ill
compar
acut
respiratori
ill
identifi
activ
surveil
winter
respiratoryviru
season
patient
chronic
obstruct
pulmonari
diseas
year
old
receiv
influenza
vaccin
result
associ
ill
ldi
ill
multivari
logist
regress
analysi
myalgia
less
like
hcov
infect
ldi
confid
limit
major
hcov
ldi
ill
exhibit
symptom
sign
acut
respiratori
ill
spirometr
result
worsen
often
ldi
mani
acut
respiratori
ill
regardless
etiolog
associ
hospit
total
ill
associ
conclus
frequenc
hcov
ldi
ill
similar
hcov
ill
less
sever
ldi
ill
accompani
multipl
respiratori
system
symptom
associ
hospit
human
coronaviru
hcov
envelop
singlestrand
positivesens
rna
viru
sinc
known
caus
common
cold
earliest
strain
group
ii
respect
emerg
sever
acut
respiratori
syndrom
sar
necessit
rethink
role
coronavirus
play
potenti
caus
moresever
respiratori
ill
even
emerg
sar
well
thereaft
hcov
infect
view
contributor
exacerb
underli
chronic
obstruct
pulmonari
diseas
copd
asthma
congest
heart
failur
sever
ill
requir
emerg
care
hospit
patient
chronic
medic
condit
renew
interest
coronavirus
led
identif
new
coronaviru
strain
group
strain
readili
cultur
clinic
specimen
tissu
cultur
wherea
group
ii
coronaviru
report
geograph
divers
region
first
describ
netherland
hong
kong
respect
associ
rang
ill
mild
febril
upperrespiratorytract
ill
sever
ill
hospit
patient
bronchiol
pneumonia
report
describ
newer
strain
occur
predominantli
children
also
adult
among
hospit
patient
hong
kong
acut
respiratorytract
infect
coronavirusesinclud
order
decreas
frequenc
detect
reversetranscript
polymeras
chain
reaction
rtpcr
patient
age
rang
year
kistler
et
al
report
presenc
adult
without
asthma
evalu
earli
onset
commoncold
symptom
prototyp
strain
hcov
group
ii
adapt
tissu
cultur
wildtyp
strain
readili
cultur
therefor
amen
isol
clinic
specimen
earlier
studi
reli
serolog
method
detect
hcov
infect
recent
rtpcr
use
detect
rna
respiratori
secret
acut
infect
rtpcr
confirm
associ
acut
respiratori
ill
howev
comparison
concord
serolog
result
detect
viru
rtpcr
correl
clinic
symptom
need
depart
veteran
affair
cooper
studi
older
adult
copd
random
receiv
trival
inactiv
influenzaviru
vaccin
tiv
intramuscularli
either
without
intranas
liveattenu
coldadapt
influenzaviru
vaccin
laiv
winter
respiratoryviru
season
monitor
prospect
occurr
acut
respiratori
ill
present
studi
compar
clinic
characterist
signific
predomin
hcov
strain
present
studi
laboratorydocu
influenza
ldi
acut
respiratori
ill
compar
frequenc
infect
detect
rtpcr
serolog
assay
character
ill
found
associ
either
patient
year
age
met
spirometr
criteria
copd
recruit
va
medic
center
describ
elsewher
patient
gave
written
inform
consent
studi
receiv
approv
respons
committe
human
experiment
follow
procedur
accord
recommend
found
helsinki
declar
revis
pulmonaryfunct
test
includ
forc
expiratori
volum
fev
percentag
predict
fev
ratio
fev
forc
vital
capac
fev
fvc
spirometr
criteria
copd
fev
predict
valu
fev
fvc
immun
occur
octob
januari
patient
receiv
tiv
influenza
season
patient
randomli
assign
ratio
receiv
intranas
either
laiv
medimmun
vaccin
formerli
aviron
tc
group
placebo
tp
group
novemb
april
patient
evalu
either
symptom
acut
respiratori
ill
fever
accompani
symptom
acut
respiratori
ill
nasal
oropharyng
nop
swab
specimen
serum
specimen
obtain
detect
viru
antibodi
respect
second
serum
specimen
obtain
week
onset
acut
respiratori
ill
specimen
store
ldi
defin
sudden
onset
respiratori
ill
plu
nopswab
cultur
posit
wildtyp
influenza
viru
b
andor
increas
endpoint
titer
serum
hemagglutin
inhibit
hai
antibodi
influenza
b
measur
describ
elsewher
chang
titer
serum
hai
antibodi
use
diagnos
ldicaus
ill
acut
respiratori
ill
occur
day
vaccin
influenza
hcovassoci
ill
defin
sudden
onset
respiratori
ill
plu
nopswab
cultur
posit
either
rtpcr
use
sarscoronaplex
kit
prodess
detect
sar
coronaviru
andor
increas
endpoint
titer
serum
antibodi
hcov
elisa
rna
rtpcr
assay
extract
nop
specimen
accord
manufactur
recommend
procedur
qiaamp
kit
qiagen
avail
nop
specimen
ill
rise
antibodi
cultur
cell
gift
lia
van
der
hoek
univers
amsterdam
netherland
rna
extract
supernat
fluid
use
qiamp
ultrasen
viru
kit
qiagen
subject
rtpcr
use
geneamp
rna
pcr
kit
appli
biosystem
spike
gene
nest
primer
amplif
cdna
genespecif
outer
primer
compris
posit
posit
sens
posit
antisens
describ
elsewher
inner
primer
design
use
netherland
isol
genbank
access
number
compris
posit
posit
sens
posit
antisens
specimen
viral
band
confirm
gel
electrophoresi
rtpcr
product
consid
posit
rtpcr
product
purifi
use
qia
quick
pcr
purif
kit
protocol
qiagen
sequenc
primer
alpha
biolaboratori
hcov
antigen
use
antibodi
elisa
produc
follow
obtain
american
type
cultur
collect
atcc
grown
cell
monolay
atcc
respect
grown
monolay
virusinfect
cell
frozen
thaw
time
supernat
fluid
clarifi
cell
debri
centrifug
viru
concentr
overnight
centrifug
viru
pellet
resuspend
pb
concentr
viru
inactiv
psoralen
compound
sigma
follow
irradi
longwavelength
uv
light
describ
elsewher
mock
antigen
prepar
way
uninfect
cell
tag
recombin
n
protein
use
antigen
elisa
detect
antibodi
express
vector
novagen
encod
n
protein
clone
ecori
noti
site
infram
downstream
seri
histidin
residu
describ
elsewher
gift
k
yuen
univers
hong
kong
hong
kong
recombin
n
protein
express
transform
singl
compet
cell
novagen
plasmid
purifi
ni
load
hitrap
chelat
system
amersham
bioscienc
accord
manufactur
instruct
brief
transform
cell
disrupt
protein
sampl
prepar
isol
inclus
bodi
via
sonic
wash
protein
sampl
load
onto
hitrap
chelat
hp
column
prepack
precharg
ni
sepharos
high
perform
protein
purifi
refold
serial
buffer
wash
column
liquid
chromatographi
fplc
system
pharmacia
lbk
biotechnolog
elut
protein
collect
fraction
fraction
analyz
presenc
protein
sdspage
protein
concentr
determin
biorad
protein
assay
biorad
laboratori
adjust
gml
elisa
mock
antigen
produc
plasmid
dna
vector
without
n
protein
gene
sequenc
procedur
viral
antigen
respect
control
use
coat
flatbottom
maxisorp
immunopl
nalg
nunc
intern
sequenc
reagent
consist
serum
seri
dilut
gener
broad
doserespons
curv
mous
antihuman
igg
fcspecif
conjug
horseradish
peroxidas
accur
chemic
scientif
peroxidas
substrat
kpl
optic
densiti
od
measur
nm
use
tecan
spectrophotomet
research
triangl
park
north
carolina
antihcov
antibodi
titer
elisa
calcul
referencelin
leastsquaresfit
method
cutoff
od
set
viral
antigen
level
least
twice
background
od
respect
mock
antigen
correspond
linear
rang
od
versu
reciprocaldilut
curv
first
episod
acut
respiratori
ill
occur
day
vaccin
includ
clinic
analys
categor
patient
term
ill
group
subsequ
ill
describ
earlier
ill
could
affect
characterist
later
ill
number
later
ill
small
ill
group
compris
whose
first
episod
acut
respiratori
ill
associ
either
ldi
ldi
either
neither
ldi
respiratori
ill
associ
describ
individu
sever
ill
assess
use
selfreport
symptombas
chronic
lung
diseas
sever
index
cldsi
develop
part
veteran
health
studi
evalu
function
statu
wellb
effect
chronic
lung
diseas
qualiti
life
cldsi
score
rang
best
sever
hospit
studi
identifi
basi
seriousadverseev
form
hospit
consid
tempor
associ
acut
respiratori
ill
occur
either
ill
month
thereaft
descript
statist
use
initi
analysi
variabl
test
fisher
exact
test
use
compar
categor
characterist
ill
group
wilcoxon
ranksum
test
use
compar
continu
characterist
p
valu
report
arbitrari
correct
multipl
comparison
p
consid
statist
signific
fev
chang
studi
visit
consid
clinic
signific
univari
logist
regress
analysi
use
identifi
univari
associ
ill
group
clinic
symptom
sign
acut
respiratori
ill
influenzavaccin
group
multivari
analysi
use
stepwis
logist
regress
identifi
factor
independ
associ
hcov
infect
p
necessari
factor
includ
logist
model
p
necessari
retain
model
total
acut
respiratori
ill
occur
among
vaccin
patient
acut
respiratori
ill
clinic
assess
patient
patient
acut
respiratori
ill
respiratori
ill
test
infect
ill
among
patient
among
patient
test
infect
clinic
assess
overal
fulli
assess
ill
posit
either
infect
tabl
number
ill
associ
time
associ
ill
pair
serum
specimen
avail
chang
titer
antibodi
either
tabl
ill
assess
rtpcr
posit
either
tabl
none
posit
sarscoronaviru
none
ill
nop
specimen
avail
posit
rtpcr
ill
pair
serum
specimen
avail
posit
hcov
infect
ill
nopswab
pair
serum
specimen
test
posit
either
tabl
proport
ill
found
posit
antibodi
test
significantli
differ
found
posit
rtpcr
ill
posit
either
posit
antibodi
test
rtpcr
patient
experienc
hcovassoci
ill
figur
ill
occur
throughout
followup
period
studi
site
major
ill
associ
occur
decemb
januari
figur
march
number
ill
greater
number
ill
figur
analysi
first
episod
acut
respiratori
ill
includ
associ
andor
associ
ldi
ldiassoci
ill
confirm
cultur
remaind
confirm
serolog
assay
ldiassoci
ill
type
influenza
viru
b
type
type
b
influenza
viru
subtyp
total
first
episod
acut
respiratori
ill
associ
ldi
either
demograph
characterist
healthcar
outcom
hospit
prednison
use
death
ill
group
list
tabl
baselin
demograph
characterist
group
patient
acut
respiratori
ill
diagnos
studi
similar
patient
ill
diagnos
studi
tabl
hcov
ldi
nonhcov
nonldi
group
prednison
use
studi
necessarili
acut
respiratori
ill
increas
level
enrol
tabl
proport
patient
use
prednison
time
studi
smaller
noill
group
ldi
group
nonhcovnonldi
group
proport
patient
hospit
studi
significantli
smaller
noill
group
nonhcovnonldi
group
p
tabl
patient
hospit
major
hospit
either
month
acut
respiratori
ill
associ
hcov
infect
andor
ldi
tabl
death
hcov
ldi
group
occur
month
acut
respiratori
ill
death
nonhcovnonldi
group
occur
month
acut
respiratori
ill
patient
ill
relat
hcov
symptom
sign
acut
respiratori
ill
found
patient
hcovrel
ill
patient
new
increas
cough
sputum
product
nasal
congest
fatigu
andor
malais
tabl
stepwis
logist
regress
analysi
myalgia
found
significantli
less
frequent
associ
hcov
ill
tabl
patient
ldi
group
less
like
receiv
vaccin
sign
symptom
proport
pa
viral
nucleic
acid
either
detect
nop
swab
specimen
b
chang
antibodi
titer
either
acut
convalesc
serum
specimen
compar
c
serolog
assay
indic
ill
posit
tient
hcov
group
significantli
differ
nonhcovnonldi
group
tabl
compar
mean
fev
acut
respiratori
ill
visit
first
episod
acut
respiratori
ill
week
later
chang
hcov
group
howev
ldi
group
nonhcovnonldi
group
significantli
lower
wors
visit
first
episod
improv
week
later
tabl
visit
first
episod
proport
ldi
group
worsen
fev
significantli
greater
hcov
group
nonhcovnonldi
group
hcov
ldi
nonhcovnonldi
group
mean
cldsi
score
increas
worsen
significantli
visit
first
episod
improv
week
later
ldi
nonhcov
nonldi
group
tabl
proport
patient
includ
among
ill
among
ill
assess
patient
infect
respiratori
ill
occur
hcovassoci
ill
also
shown
patient
ill
associ
either
laboratorydocu
influenza
ldi
hcov
ill
hcov
ill
ldi
ldi
concurr
hcov
infect
ill
nonhcovnonldi
ill
hcov
ill
either
ill
nonhcovnonldi
ill
row
repres
patient
report
site
identifi
code
us
state
puerto
rico
pr
left
graph
site
state
pr
report
ill
associ
hcov
state
state
pr
hcovassoci
ill
report
site
florida
southern
northern
california
texa
virginia
studi
site
report
ill
virginia
ill
alabama
ill
minnesota
ill
missouri
ill
texa
ill
cumul
number
ill
hcovassoci
ill
regardless
whether
first
episod
acut
respiratori
ill
includ
associ
hcov
hcov
ldi
graph
calendar
month
cumul
number
occur
begin
correspond
month
hcovassoci
ill
occur
end
occur
strain
period
ill
predomin
februari
worsen
cldsi
score
visit
first
episod
largest
ldi
group
eight
patient
rise
antibodi
titer
patient
ill
first
episod
acut
respiratori
ill
posit
rtpcr
sequenc
rtpcr
product
locat
posit
similar
genbank
access
number
similar
nucleotid
level
one
patient
rise
antibodi
titer
associ
first
episod
without
concomit
evid
infect
either
tabl
ill
associ
symptom
acut
respiratori
ill
patient
hospit
associ
hcov
receiv
prednison
includ
receiv
associ
none
die
hcov
infect
clinic
signific
popul
older
patient
copd
chronic
ill
frequenc
infect
associ
acut
respiratori
ill
similar
ldi
infect
may
underestim
number
hcovassoci
ill
ill
meet
criteria
evalu
assess
endofstudi
serum
sampl
obtain
unabl
estim
frequenc
hcov
infect
patient
acut
respiratori
ill
hcovassoci
ill
identifi
divers
geograph
site
within
continent
unit
state
copd
chronic
obstruct
pulmonari
diseas
fev
fvc
ratio
forc
expiratori
volum
forc
vital
capac
hcov
human
coronaviru
ldi
laboratorydocu
influenza
na
applic
ppfev
percentag
predict
fev
includ
b
acut
respiratori
ill
met
criteria
evalu
studi
c
p
higher
valu
ldi
group
vs
nonhcovnonldi
group
p
higher
valu
noill
group
vs
nonhcovnonldi
group
p
higher
proport
group
hcov
ldi
vs
group
e
p
higher
proport
group
hcov
ldi
p
nonhcovnonldi
group
vs
ldionli
group
f
p
higher
proport
nonhcovnonldi
group
vs
ldionli
group
p
noill
group
g
p
lower
proport
noill
group
vs
nonhcovnonldi
group
h
p
higher
mean
number
nonhcovnonldi
group
vs
noill
group
p
lower
proport
nonhcovnonldi
group
vs
noill
group
likelihood
andor
ci
puerto
rico
hcovassoci
infect
character
new
increas
cough
sputum
product
nasal
congest
fatigu
andor
malais
multivari
logist
regress
analysi
hcovassoci
ill
statist
less
like
ldi
associ
myalgia
henc
hcov
infect
difficult
distinguish
ldi
influenzavaccin
popul
whose
influenzaassoci
ill
may
less
sever
unvaccin
popul
ill
associ
either
hcov
ldi
easili
distinguish
statist
hcov
previou
analys
influenza
like
associ
fever
myalgia
worsen
fev
noninfluenza
acut
respiratori
ill
acut
respiratori
ill
matter
caus
associ
signific
worsen
cldsi
score
basi
chang
fev
hcov
appear
less
sever
serolog
rtpcr
assay
use
complementari
test
detect
infect
ill
posit
hcov
serolog
rtpcr
criteria
delay
collect
nop
specimen
onset
symptom
acut
respiratori
ill
well
long
interv
year
collect
assay
sampl
may
result
number
viral
copi
threshold
detect
rtpcr
assay
infect
associ
ill
older
chronic
ill
popul
might
expect
basi
previou
report
although
rate
similar
found
present
studi
report
instanc
virusassoci
respiratorytract
infect
patient
copd
report
greenberg
et
al
due
either
communitybas
studi
elderli
patient
conduct
graat
et
al
report
respiratori
infect
due
frequenc
second
rhinovirus
present
studi
also
predomin
number
studi
wherea
predomin
recent
studi
identifi
small
number
ill
associ
recent
describ
cocircul
winter
respiratoryviru
season
geograph
divers
site
unit
state
spectrum
ill
similar
strain
respiratori
infect
due
hcov
associ
hospit
glezen
et
al
report
patient
hospit
acut
respiratori
condit
infect
relat
either
patient
adult
year
age
falsey
et
al
report
hospit
elderli
patient
concomit
infect
present
studi
hospit
associ
respiratori
infect
ill
group
month
immedi
visit
first
episod
acut
respiratori
ill
throughout
studi
followup
lower
rate
hospit
group
without
acut
respiratori
ill
qualifi
evalu
includ
b
p
lower
mean
valu
ill
ill
c
p
lower
mean
valu
ill
ill
p
higher
mean
valu
week
ill
ill
e
p
higher
mean
valu
week
ill
ill
f
p
higher
proport
ldi
group
group
andor
nonhcovnonldi
group
g
p
higher
mean
valu
ill
ill
within
group
h
p
higher
mean
valu
ill
week
ill
p
higher
proport
ldi
group
nonhcovnonldi
group
present
studi
studi
followup
overal
mean
number
hospit
per
patient
hcovinfect
group
doubl
noill
group
ill
group
prednison
use
increas
studi
although
commonli
thought
associ
cold
month
hcov
infect
report
also
occur
time
year
season
hcov
tropic
subtrop
area
restrict
present
studi
followup
period
extend
octob
april
hcov
infect
detect
throughout
period
although
frequent
decemb
januari
result
present
studi
underscor
clinic
import
hcov
infect
older
patient
copd
clinic
characterist
hcov
difficult
distinguish
character
influenza
least
influenzavaccin
popul
although
frequent
hcov
strain
identifi
cocircul
season
studi
older
chronic
ill
popul
necessari
determin
genet
evolut
circul
viral
strain
impact
contemporari
strain
clinic
characterist
sever
ill
season
infect
